FOLH1 and posterior cortical atrophy: Tumor cells identified as PSMA-avid on PET/CT imaging can be targeted and eliminated with PSMA-labeled Lutetium-177 (<sup>177</sup>Lu-PSMA) therapy.<h4>Case presentation</h4>A sixty-eight years old patient who had metastatic castration-resistant PCa was reported in this study.